Hydralazine (HCl)

Overview

Sorafenib as sorafenib tosylate is an antineoplastic agent and shows its activity by kinase inhibitor.Sorafenib tosylate has the chemical name 4-(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)N2methylpyridine-2-carboxamide 4-methylbenzenesulfonate

Categories

• 12 Cardiovascular drugs
  • 12.3 Anti-hypertensives
  • 12.3.7 Direct vasodilators

Page headings

Primary Characterstics

Indications

Pharmacokinetics

Contraindications

Drug Interactions

Side Effects

The severe or irreversible adverse effects of Sorafenib, which give rise to further complications include Hypertension, Hemorrhage, Myocardial infarction, gastrointestinal perforation, drug induced hepatitis.

The symptomatic adverse reactions produced by Sorafenib are more or less tolerable and if they become severe, they can be treated symptomatically, these include Fatigue, Nausea, Alopecia, Anorexia, Diarrhea, Abdominal pain, Weight loss, Alopecia, Rash.

Dosage

Hydralazine (HCl)'s dosage details are as follows:

Dose	Single Dose	Frequency	Route	Instructions
Adult Dosage
100 to 300 mg	200 (200)	As recommended.	PO	Maintanace, as required.
25 mg	25 (25)	6 hourly	PO	Initially for Several Weeks
Paedriatic Dosage (20kg)
0.1 to 0 mg/kg	0.05 (0.05)	As recommended.	Intra Muscular	Initially for Once or repeated after 30 Minutes
0.25 to 0.5 mg/kg	0.38 (0.375)	6 hourly	Oral	Maintenance, As Required
0.1 to 0 mg/kg	0.05 (0.05)	As recommended.	Slow IV	Initially for Once or repeated after 30 Minutes
Neonatal Dosage (3kg)
0.2 mg/kg	0.2 (0.2)	As recommended.	Intra Muscular	Initially for Once or repeated after 30 Minutes
0.25 to 0.5 mg/kg	0.38 (0.375)	6 hourly	Oral	Maintenance, As Required
0.2 mg/kg	0.2 (0.2)	As recommended.	Slow IV	Initially for Once or repeated after 30 Minutes

High Risk Groups

Warning / Precautions

Storage Conditions

Interference in Pathology

Brands / Trade Names of Hydralazine (HCl)

Manufacturers of Hydralazine (HCl) in Pakistan

Back to top